News | Radiation Therapy | April 18, 2016

Brainlab Licenses Algorithm for Patient-Specific Cranial Radiosurgery

New algorithm creates patient-specific arc trajectories by penalizing geometric collisions with critical structures and rewarding steep dose gradients towards such structures

Brainlab, Dalhousie University, cranial radiosurgery, treatment planning algorithm

April 18, 2016 — Brainlab AG and Dalhousie University, Atlantic Canada’s leading research-intensive university, have entered into an exclusive intellectual property license agreement for integration with next-generation radiosurgery software.

The exclusive license covers technology for patient-tailored, optimized arc-trajectories aimed at minimizing radiation dose to organs at risk without compromising target coverage. The new algorithm creates a suitability ranking for every gantry- and couch-position based on geometric overlap of multiple risk organs and the target volume, and considers the relative depth of structures and dose tolerances. The algorithm can reward regions of approach which allow the most rapid dose fall-off toward specific organs at risk. The optimization can be applied to fixed couch arcs as well as simultaneous gantry-couch movements.

“We have developed an effective method for trajectory-based treatment planning and delivery, often referred to as the Four-Pi approach. In addition to minimizing peripheral dose, the new algorithm alleviates the need for beam modulation, increasing the efficiency of planning and treatment delivery,” explained James Robar, Ph.D., FCCPM, chief of medical physics, Dalhousie University. “For patients, this means that we can further limit dose to healthy organs surrounding the tumor, without extending treatment times.”

For more information: www.brainlab.com

Related Content

Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
Videos | Lung Cancer | January 29, 2019
Gregory Videtic, M.D., staff physician in radiation oncology at the Cleveland Clinic, and David Johnstone, M.D., prof